Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy

被引:16
|
作者
Xiao, Yuchen [1 ,2 ]
Zhu, Tianchuan [1 ]
Zeng, Qi [3 ]
Tan, Qingqin [1 ]
Jiang, Guanmin [4 ]
Huang, Xi [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Infect & Immun, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Guangdong, Peoples R China
[2] Southern Marine Sci & Engn Guangdong Lab, Zhuhai 519000, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Oncol, Zhuhai 519000, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Clin Lab, Zhuhai 519000, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
PD-L1; Photothermal ablation; Biomimetic nanoparticles; Tumor microenvironment; Colorectal cancer; RESISTANCE;
D O I
10.1016/j.actbio.2022.11.043
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand pro-grammed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-L1 inhibitors is limited in some colorec-tal cancers within the immunosuppressive tumor microenvironment (such as when there is a lack of immune cell infiltration). Herein, anti-PD-L1 functionalized biomimetic polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs) were developed for synergistic anti-tumor treatment by combining PD-1/PD-L1 blockade with photothermal ablation. PDA/GNS@aPD-L1 NPs were prepared by encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane isolated from anti-PD-L1 single-chain variable fragment (scFv) over-expressing cells. In ad-dition to disrupting PD-1/PD-L1 immunosuppressive signals, the anti-PD-L1 scFv on the membrane of PDA/GNS@aPD-L1 NPs was conducive to the accumulation of PDA-GNS at tumor sites. Importantly, the tu-mor photothermal ablation induced by PDA-GNS could reverse the immunosuppressive tumor microenvi-ronment, thereby further improving the efficiency of PD-1/PD-L1 blockade therapy. In this study, the syn-thetized PDA/GNS@aPD-L1 NPs exhibited good biocompatibility, efficient photothermal conversion ability, and enhanced tumor-targeting ability. In vivo studies revealed that a PDA/GNS@aPD-L1 NP-based thera-peutic strategy significantly inhibited tumor growth, and prolonged overall survival by further promot-ing the maturation of dendritic cells (DCs), increasing the infiltration of CD8 + T cells, and decreasing the number of immunosuppressive cells (such as regulatory T cells and myeloid-derived suppressive cells). Collectively, the developed PDA/GNS@aPD-L1 NP-based therapeutic strategy combines PD-1/PD-L1 block-ade with photothermal ablation, which could remodel the tumor microenvironment for effective clinical colorectal cancer therapy.Statement of significance Immunosuppressive tumor microenvironment is the main challenge facing programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy. By encapsulating photothermal nanopar-ticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane over-expressing anti-PD -L1 single-chain variable fragment, we constructed anti-PD-L1 functionalized biomimetic nanoparticles (PDA/GNS@aPD-L1 NPs). By specific binding to the PD-L1 present on tumor cells, PDA/GNS@aPD-L1 NPs could disrupt PD-1/PD-L1 immunosuppression signaling, and effectively deliver PDA-GNS targeting to tu-mor sites. Additionally, PDA-GNS-mediated local photothermal ablation of tumors promoted the release of tumor-associated antigens and thus activated anti-tumor immune responses. Meanwhile, hyperthermia facilitates immune cell infiltration by increasing tumor vascular permeability. Therefore, PDA/GNS@aPD-L1 NPs could sensitize tumors to PD-1/PD-L1 blockade therapy by remodeling the immunosuppressive tumor microenvironment, which provides a new strategy for tumor treatment.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:451 / 466
页数:16
相关论文
共 50 条
  • [1] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [2] Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Ichikawa, Yoshiki
    Kobayashi, Atsushi
    Shibahara, Tomoyuki
    Yanagawa, Yojiro
    Higuchi, Hidetoshi
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1573 - 1583
  • [3] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    BLOOD, 2018, 132
  • [4] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Chen, Daniel S.
    Irving, Bryan A.
    Hodi, F. Stephen
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6580 - 6587
  • [5] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu Qiang
    Li Chun-Sheng
    中华医学杂志英文版, 2017, 130 (08) : 986 - 992
  • [6] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu, Qiang
    Li, Chun-Sheng
    CHINESE MEDICAL JOURNAL, 2017, 130 (08) : 986 - 992
  • [7] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [8] Programmed death-1 and programmed death ligand-1 blockade for advanced urothelial carcinoma
    Guo, Jhe-Cyuan
    Tsai, Yu-Chieh
    Pu, Yeong-Shiau
    UROLOGICAL SCIENCE, 2019, 30 (01) : 2 - 7
  • [9] Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma
    Montasser, Ahmed
    Beaufrere, Aurelie
    Cauchy, Francois
    Bouattour, Mohamed
    Soubrane, Olivier
    Albuquerque, Miguel
    Paradis, Valerie
    HISTOPATHOLOGY, 2021, 79 (01) : 36 - 46
  • [10] Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer.
    Miyashita, Hirotaka
    Mikami, Takahisa
    Satoi, Sera
    Cruz, Christina
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)